Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells

3 Nov 2014

Abstract excerpt

BACKGROUND: Accumulating preclinical and clinical evidence implicates epithelial-mesenchymal transition (EMT) in acquired resistance to anticancer drugs; however, mechanisms by which the mesenchymal state determines drug resistance remain unknown. RESULTS: To explore a potential role for altered cellular metabolism in EMT and associated drug resistance, we analyzed the metabolome and transcriptome of three lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer, Hypoxia, and Metabolism
Share to thermodynamics and calorimetric analyses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25379179
DOI: 10.1186/2049-3002-2-20

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cellsPMID 25379179Read ↗

Inhibition of pyruvate dehydrogenase kinase redirects NSCLC cell metabolism and counteracts development of resistance to epidermal growth factor receptor tyrosine kinase inhibitorsSemantic proximity Read ↗

Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?Semantic proximity Read ↗

Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of ResistanceSemantic proximity Read ↗

Mitochondrial metabolism in cancer transformation and progressionSemantic proximity Read ↗

Metabolic reprogram associated with epithelial-mesenchymal transition in tumor progression and metastasisSemantic proximity Read ↗

Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer.Semantic proximity Read ↗

Pyruvate dehydrogenase kinase expression profile is a biomarker for cancer sensitivity to dichloroacetate-mediated growth inhibitionSemantic proximity Read ↗

Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated StatesSemantic proximity Read ↗

Mitochondrial metabolism as a potential novel therapeutic target for lung adenocarcinomaSemantic proximity Read ↗

A non-canonical glucose metabolic rewiring enables resistance to cancer targeted therapySemantic proximity Read ↗

Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancerSemantic proximity Read ↗

PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.